Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

139 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Long-term outcome of imatinib 400 mg compared to imatinib 600 mg or imatinib 400 mg daily in combination with cytarabine or pegylated interferon alpha 2a for chronic myeloid leukaemia: results from the French SPIRIT phase III randomised trial.
Guilhot F, Rigal-Huguet F, Guilhot J, Guerci-Bresler AP, Maloisel F, Rea D, Coiteux V, Gardembas M, Berthou C, Vekhoff A, Jourdan E, Berger M, Fouillard L, Alexis M, Legros L, Rousselot P, Delmer A, Lenain P, Escoffre Barbe M, Gyan E, Bulabois CE, Dubruille V, Joly B, Pollet B, Cony-Makhoul P, Johnson-Ansah H, Mercier M, Caillot D, Charbonnier A, Kiladjian JJ, Chapiro J, Penot A, Dorvaux V, Vaida I, Santagostino A, Roy L, Zerazhi H, Deconinck E, Maisonneuve H, Plantier I, Lebon D, Arkam Y, Cambier N, Ghomari K, Miclea JM, Glaisner S, Cayuela JM, Chomel JC, Muller M, Lhermitte L, Delord M, Preudhomme C, Etienne G, Mahon FX, Nicolini FE; France Intergroupe des Leucémies Myéloïdes Chroniques, Fi-LMC. Guilhot F, et al. Among authors: guilhot j. Leukemia. 2021 Aug;35(8):2332-2345. doi: 10.1038/s41375-020-01117-w. Epub 2021 Jan 22. Leukemia. 2021. PMID: 33483613 Clinical Trial.
Imatinib in combination with cytarabine for the treatment of Philadelphia-positive chronic myelogenous leukemia chronic-phase patients: rationale and design of phase I/II trials.
Guilhot F, Gardembas M, Rousselot P, Tulliez M, Vigier M, Buzyn A, Rigal-Huguet F, Legros L, Michallet M, Berthou C, Najman A, Maloisel F, Mahon FX, Facon T, Berthaud P, Guilhot J; CML French Group. Guilhot F, et al. Among authors: guilhot j. Semin Hematol. 2003 Apr;40(2 Suppl 2):92-7. doi: 10.1053/shem.2003.50048. Semin Hematol. 2003. PMID: 12783382 Review.
Interferon therapy in chronic myelogenous leukemia.
Guilhot F, Roy L, Guilhot J, Millot F. Guilhot F, et al. Among authors: guilhot j. Hematol Oncol Clin North Am. 2004 Jun;18(3):585-603, viii. doi: 10.1016/j.hoc.2004.03.002. Hematol Oncol Clin North Am. 2004. PMID: 15271394 Review.
Immunotherapeutic approaches in chronic myelogenous leukemia.
Guilhot F, Roy L, Saulnier PJ, Guilhot J, Barra A, Gombert JM, Turhan A. Guilhot F, et al. Among authors: guilhot j. Leuk Lymphoma. 2008 Apr;49(4):629-34. doi: 10.1080/10428190801927510. Leuk Lymphoma. 2008. PMID: 18398723 Review.
Interferon in chronic myeloid leukaemia: past and future.
Guilhot F, Roy L, Saulnier PJ, Guilhot J. Guilhot F, et al. Among authors: guilhot j. Best Pract Res Clin Haematol. 2009 Sep;22(3):315-29. doi: 10.1016/j.beha.2009.10.005. Best Pract Res Clin Haematol. 2009. PMID: 19959083 Review.
The addition of daunorubicin to imatinib mesylate in combination with cytarabine improves the response rate and the survival of patients with myeloid blast crisis chronic myelogenous leukemia (AFR01 study).
Deau B, Nicolini FE, Guilhot J, Huguet F, Guerci A, Legros L, Pautas C, Berthou C, Guyotat D, Cony-Makhoul P, Gardembas M, Michallet M, Hayette S, Cayuela JM, Weiss IR, Réa D, Castaigne S, Mahon FX, Guilhot F, Rousselot P. Deau B, et al. Among authors: guilhot f, guilhot j. Leuk Res. 2011 Jun;35(6):777-82. doi: 10.1016/j.leukres.2010.11.004. Epub 2010 Dec 10. Leuk Res. 2011. PMID: 21145590 Clinical Trial.
Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia.
Preudhomme C, Guilhot J, Nicolini FE, Guerci-Bresler A, Rigal-Huguet F, Maloisel F, Coiteux V, Gardembas M, Berthou C, Vekhoff A, Rea D, Jourdan E, Allard C, Delmer A, Rousselot P, Legros L, Berger M, Corm S, Etienne G, Roche-Lestienne C, Eclache V, Mahon FX, Guilhot F; SPIRIT Investigators; France Intergroupe des Leucémies Myéloïdes Chroniques (Fi-LMC). Preudhomme C, et al. Among authors: guilhot f, guilhot j. N Engl J Med. 2010 Dec 23;363(26):2511-21. doi: 10.1056/NEJMoa1004095. N Engl J Med. 2010. PMID: 21175313 Free article. Clinical Trial.
Curing chronic myeloid leukemia.
Rea D, Rousselot P, Guilhot J, Guilhot F, Mahon FX. Rea D, et al. Among authors: guilhot f, guilhot j. Curr Hematol Malig Rep. 2012 Jun;7(2):103-8. doi: 10.1007/s11899-012-0117-2. Curr Hematol Malig Rep. 2012. PMID: 22410764 Review.
Tolerability and efficacy of pegylated interferon-α-2a in combination with imatinib for patients with chronic-phase chronic myeloid leukemia.
Johnson-Ansah H, Guilhot J, Rousselot P, Rea D, Legros L, Rigal-Huguet F, Nicolini FE, Mahon FX, Preudhomme C, Guilhot F. Johnson-Ansah H, et al. Among authors: guilhot f, guilhot j. Cancer. 2013 Dec 15;119(24):4284-9. doi: 10.1002/cncr.28328. Epub 2013 Sep 16. Cancer. 2013. PMID: 24105694 Free article. Clinical Trial.
Pioglitazone together with imatinib in chronic myeloid leukemia: A proof of concept study.
Rousselot P, Prost S, Guilhot J, Roy L, Etienne G, Legros L, Charbonnier A, Coiteux V, Cony-Makhoul P, Huguet F, Cayssials E, Cayuela JM, Relouzat F, Delord M, Bruzzoni-Giovanelli H, Morisset L, Mahon FX, Guilhot F, Leboulch P; French CML Group. Rousselot P, et al. Among authors: guilhot f, guilhot j. Cancer. 2017 May 15;123(10):1791-1799. doi: 10.1002/cncr.30490. Epub 2016 Dec 27. Cancer. 2017. PMID: 28026860 Free PMC article. Clinical Trial.
139 results